Eli Lilly reported that retatrutide beat Novo’s Ozempic 2 mg in a head-to-head phase 3 trial, delivering deeper reductions in both blood sugar and body weight over 80 weeks in almost 1,300 adults with Type 2 diabetes. The result gives Lilly a direct comparative win in one of the most commercially important drug classes in biopharma.
Participants entered the open-label study with diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor. Baseline A1C averaged 8.3% and ranged from 7.0% to 10.5%. After 80 weeks of weekly dosing, A1C fell 2.2% in both the 9 mg and 12 mg retatrutide groups, compared with 1.8% in the Ozempic arm, meeting the trial’s primary endpoint with a statistically significant difference.
The Data
The weight-loss separation was larger than the A1C gap. Patients receiving 9 mg and 12 mg of retatrutide lost 19.5% and 20.9% of body weight, respectively, versus 9.4% for patients on Ozempic. That allowed Lilly to hit the key secondary endpoint.
Lilly also said retatrutide produced greater improvements than Ozempic across certain cardiovascular risk factors, including non-HDL cholesterol, triglycerides and systolic blood pressure. The company has not yet shared more detailed data from the trial, so the current readout is enough to establish directional advantage, but not yet enough to fully judge how durable or clinically differentiated those secondary measures may be.
Safety and tolerability were more mixed. On the 12-mg retatrutide dose, 7.9% of patients discontinued treatment because of adverse events, compared with 2.7% on Ozempic. Rates of diarrhea, nausea and vomiting were higher on retatrutide, at least at the 12-mg dose, than on Novo’s drug. The largest gap was in diarrhea, which affected up to 32.7% of people on retatrutide and 26.4% of people on Ozempic. Not every gastrointestinal endpoint went against Lilly’s candidate, however: constipation was reported in 19.8% of Ozempic patients versus up to 14.2% on retatrutide.
What The Readout Means
The strategic signal is that Lilly is building a case for retatrutide not just as another entrant, but as a drug that may push efficacy expectations higher in diabetes and weight management. Retatrutide is an investigational agonist of GLP-1, GIP and glucagon, and this study suggests Lilly may be able to market the triple-agonist mechanism around superior metabolic effect rather than incremental convenience.
That said, the readout also reinforces a pattern already familiar in obesity and diabetes drug development: stronger efficacy can come with a narrower tolerability margin for some patients. The commercial question is not simply whether retatrutide works better than Ozempic on headline measures, but how physicians and payers will value the tradeoff if discontinuation rates remain higher at top doses.
Lilly has already reported data from a placebo-controlled trial in Type 2 diabetes and has also delivered data on retatrutide in obesity patients. The company said it plans to file for FDA approval of the drug candidate in the first quarter of 2027. Between now and then, fuller phase 3 data will matter because this topline win establishes competitive positioning, but the depth of that advantage will depend on details Lilly has not yet released.
